Anti Viral
Biovudine®
Brand Name:
Biovudin®
Dosage:
100 mg & 150 mg
Generic Name:
Lamivudine
Pharmacotherapeutic Group:
Antiviral (systemic)
Therapeutic Indication:
- Lamivudine: HIV Infection: Lamivudine in combination with other antiretroviral agents is indicated for the treatment of HIV infection.
- Chronic hepatitis B (HBV): Treatment of chronic hepatitis B associated with evidence of viral replication and active liver elimination.
Dosage and Administration:
HIV Infection:
- Adults – 300mg/day, administered as either 150mg twice daily or 300mg once daily, in combination with other antiretroviral agents.
- Children (3 months up to 16 years of age) – 4mg/kg twice daily (up to a maximum of 150mg twice a day) administered with other antiretroviral agents.
Chronic Hepatitis B:
- Adults – 100mg once daily. Safety and efficacy of treatment beyond 1year have not been established, and the optimum duration treatment is not known.
- Children (2 to 17 years of age) – 3mg/kg once daily, up to a maximum daily dose of 100mg. safety and effectiveness beyond 1year have not been established and the optimum duration of treatment is not known.
Side Effects:
- CNS: Headache; neuropathy; dizziness; sleep disturbances; depression; insomnia and other sleep disorders; depressive disorders.
- DERMATOLOGIC: Rash; alopecia; pruritus.
- GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain/cramps; dyspepsia; stomatitis.
- HEMATOLOGIC: Anemia; neutropenia; hyperglycemia; weakness; lactic acidosis; lymphadenopathy; splenomegaly; lactic steatosis.
- RESPIRATORY: Nasal signs and symptoms; cough; paresthesia; abnormal breath sounds/wheezing.
- OTHER: Malaise; fatigue; fever; chills; myalgia; arthralgia; pancreatitis; elevated liver enzymes; musculoskeletal pain; anaphylaxis; urticaria; rhabdomyolysis; peripheral neuropathy; hepatic steatosis; muscle weakness with CPK elevation; posttreatment exacerbation of hepatitis.